Evaluating the efficacy of upadacitinib in patients with moderate rheumatoid arthritis: a post-hoc analysis of the SELECT phase 3 trials.

Conaghan, Philip G; Pavelka, Karel; Hsieh, Song-Chou; Bonnington, Terri-Leigh; Kent, Toby C; Marchbank, Katie; Edwards, Christopher J

Conaghan, Philip G; Pavelka, Karel; Hsieh, Song-Chou; Bonnington, Terri-Leigh; Kent, Toby C; Marchbank, Katie; Edwards, Christopher J.

Afiliación

Conaghan PG; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Pavelka K; National Institute for Health and Care Research (NIHR), Leeds Biomedical Research Centre, Leeds, UK.
Hsieh SC; Institute of Rheumatology, Charles University, Prague, Czech Republic.
Bonnington TL; International Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Kent TC; Medical, AbbVie Ltd, Chicago, IL, USA.
Marchbank K; Medical, AbbVie Ltd, Chicago, IL, USA.
Edwards CJ; Medical, AbbVie Ltd, Chicago, IL, USA.

Rheumatol Adv Pract ; 7(1): rkad017, 2023.

Article en En | MEDLINE | ID: mdl-36794283

Palabras clave

JAK inhibitors; RA; moderate; moderate disease activity; upadacitinib

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Rheumatol Adv Pract Año: 2023 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google